Home Study finds key GSK-Theravance lung drug didn't extend lives
 

Keywords :   


Study finds key GSK-Theravance lung drug didn't extend lives

2015-09-09 01:33:31| Biotech - Topix.net

A closely watched study of GlaxoSmithKline plc's Breo Ellipta respiratory treatment failed to prove that it extends patients' lives, denying the drugmaker a much-needed marketing edge in its most lucrative - but declining - medicine category. It was a disappointing deja vu for the British drugmaker, which previously failed to prove the same benefit for its much older respiratory treatment Advair, long the company's top seller with revenue of $8.3 billion as recently as 2013.

Tags: key study lives drug

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
27.11topps now psa10
27.11 THE ORAL CIGARETTES SUCK MY WORLD
27.11 E
27.113DS .SD()
27.11181
27.11YAMAHA KUSHITANI LL
27.11tsnomi.com
27.11
More »